Seroquel (Quetiapine) is More Likely to Cause Myoclonus Than Carbamazepine
Between Seroquel and carbamazepine, quetiapine is more likely to cause myoclonus as a direct adverse effect, while carbamazepine is actually used to treat myoclonus and only rarely induces it in specific contexts.
Evidence from Drug Labels and Systematic Reviews
The FDA label for Seroquel does not explicitly list myoclonus as a common adverse effect in its standard tables 1. However, a 2025 systematic review of drug-induced myoclonus identified both quetiapine and carbamazepine as having Level A evidence (the highest level) for causing myoclonus 2. This appears contradictory until you examine the clinical context more carefully.
Quetiapine and Myoclonus
Multiple case reports document quetiapine-induced myoclonus:
- A 64-year-old man with schizophrenia developed dose-related myoclonic jerks on higher doses of quetiapine, which completely resolved with dose reduction 3
- A case report documented quetiapine causing myoclonus with muscular artifacts on EEG that could be mistaken for epileptic activity 4
The mechanism appears related to quetiapine's serotonergic effects, as the systematic review categorizes drug-induced myoclonus into three types, with Type 1 being serotonin syndrome-related 2. Quetiapine has serotonin receptor activity that can contribute to this adverse effect.
Carbamazepine and Myoclonus: A Different Story
The relationship between carbamazepine and myoclonus is more nuanced:
Carbamazepine is actually used to TREAT myoclonus, not cause it. The 2015 European Resuscitation Council guidelines note that "clonazepam, sodium valproate and levetiracetam are antimyoclonic drugs" but do not list carbamazepine as causing myoclonus 5.
However, carbamazepine can induce myoclonus in specific, rare circumstances:
- Non-epileptic myoclonus has been documented in children with benign epilepsy syndromes treated with carbamazepine 6, 7
- Epileptic negative myoclonus (brief loss of muscle tone) can be induced in children with benign childhood epilepsy with centrotemporal spikes 8
- These cases typically involve pediatric epilepsy patients and represent a paradoxical worsening of seizure types
The carbamazepine FDA label mentions "a case of aseptic meningitis, accompanied by myoclonus" in a patient taking carbamazepine with other medications, but this was in combination therapy 9.
Clinical Implications
If a patient on both medications develops myoclonus, suspect quetiapine first. The approach should be:
- Assess timing: Did myoclonus start after quetiapine initiation or dose increase?
- Check quetiapine levels: The interaction between these drugs is critical - carbamazepine induces CYP3A4 and reduces quetiapine levels by a factor of 10 10. Paradoxically, if carbamazepine is discontinued, quetiapine levels will spike dramatically, potentially worsening myoclonus
- Consider dose reduction of quetiapine first if myoclonus is present, as this was effective in documented cases 3
- Rule out serotonin syndrome: Check for other features like hyperthermia, altered mental status, autonomic instability
Important Caveat About Drug Interaction
The combination of carbamazepine and quetiapine creates a major pharmacokinetic interaction that requires 10-fold higher doses of quetiapine to achieve therapeutic levels 10. This interaction is often overlooked but highly clinically relevant. If carbamazepine is discontinued, quetiapine toxicity may emerge rapidly.
Bottom Line
Quetiapine is the more likely culprit for myoclonus in a patient taking both medications, based on case reports of dose-dependent myoclonus that resolves with dose reduction 2, 3. Carbamazepine-induced myoclonus is rare and typically occurs only in specific pediatric epilepsy syndromes 6, 8, 7. The massive drug interaction between these agents complicates the clinical picture and must be considered in any management decision 10.